跳转至内容
Merck
CN
  • Determination of amphetamine and methylphenidate in exhaled breath of patients undergoing attention-deficit/hyperactivity disorder treatment.

Determination of amphetamine and methylphenidate in exhaled breath of patients undergoing attention-deficit/hyperactivity disorder treatment.

Therapeutic drug monitoring (2014-01-24)
Olof Beck, Niclas Stephanson, Sören Sandqvist, Johan Franck
摘要

It has been discovered recently that exogenous substances are detectable in exhaled breath after intake. Exhaled breath therefore constitutes a new possible matrix in clinical pharmacology and toxicology. The present work was aimed at exploring this possibility further by a study on patients treated for attention-deficit/hyperactivity disorder with D-amphetamine and methylphenidate. Thirteen patients (age range: 32-61 years; 5 women) were included in the study, and breath and urine samples were collected at different times in the dose interval. Analyses of breath and urine samples were done with liquid chromatography-mass spectrometry methods. Urine was examined for amphetamine, methylphenidate, and its metabolite ritalinic acid. Among the 9 patients who received D-amphetamine medication in daily doses of 20-100 mg, amphetamine was detected in all subjects in amounts ranging from 1200 to 30,800 picogram per filter. Among 8 patients receiving methylphenidate medication in daily doses of 80-400 mg, it was detected and quantified in 7 of the cases in amounts ranging from 150 to 10,400 picogram per filter and ritalinic acid was detected and quantified in 3 of the cases ranging from 35 to 360 picogram per filter. In 1 case, methylphenidate was only detectable in breath and urine, whereas ritalinic acid was quantifiable in urine, which could indicate noncompliance, with the 4 hours of dose regimen prescribed. In a number of cases, the sampling was performed 24 hours after the last dose intake. Identification of amphetamine and methylphenidate was based on correct chromatographic retention time and correct product ion ratio with detection performed in selected reaction monitoring mode. The results confirm that amphetamine is present in exhaled breath after intake and demonstrate for the first time the presence of methylphenidate and ritalinic acid after its intake. This gives further support to the potential use of exhaled breath for detecting drug intake.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
乙腈, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
甲醇, suitable for HPLC, ≥99.9%
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
甲醇, HPLC Plus, ≥99.9%
Sigma-Aldrich
乙腈, ACS reagent, ≥99.5%
Sigma-Aldrich
乙腈, anhydrous, 99.8%
Sigma-Aldrich
甲醇, anhydrous, 99.8%
Sigma-Aldrich
乙腈, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
乙腈, ≥99.9% (GC)
Sigma-Aldrich
甲醇, Laboratory Reagent, ≥99.6%
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, suitable as ACS-grade LC reagent, ≥99.9%
Sigma-Aldrich
甲醇, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.8% (GC)
Sigma-Aldrich
甲醇, ACS spectrophotometric grade, ≥99.9%
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
乙腈, suitable for HPLC-GC, ≥99.8% (GC)
USP
木精, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
甲醇, BioReagent, ≥99.93%
Supelco
甲醇, analytical standard
Supelco
甲醇, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
乙腈, biotech. grade, ≥99.93%
Sigma-Aldrich
乙腈, electronic grade, 99.999% trace metals basis
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
甲酸, ≥95%, FCC, FG
Sigma-Aldrich
乙腈, suitable for DNA synthesis, ≥99.9% (GC)
Supelco
乙腈(纯品), Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
乙腈, analytical standard
Sigma-Aldrich
乙腈, ReagentPlus®, 99%
Sigma-Aldrich
甲醇, puriss., meets analytical specification of Ph Eur, ≥99.7% (GC)
Sigma-Aldrich
乙腈, ≥99.5% (GC)